Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ultra-sensitive, tumor-informed ctDNA profiling in pembrolizumab-treated esophagogastric cancer patients predicts clinical responses.
Nixon AB, Navarro FCP, Zhou KI, Abbott C, McDaniel L, Howard L, Brady JC, Liu Y, Jia J, Niedzwiecki D, Strickler J, Boyle SM, Chen RO, Uronis H. Nixon AB, et al. Among authors: strickler j. Res Sq [Preprint]. 2024 Dec 18:rs.3.rs-5349536. doi: 10.21203/rs.3.rs-5349536/v1. Res Sq. 2024. PMID: 39764133 Free PMC article. Preprint.
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, Cohn A, Starodub A, Arrowood C, Haley S, Meadows KL, Morse MA, Uronis HE, Blobe GC, Hsu SD, Zafar SY, Hurwitz HI. Strickler JH, et al. Invest New Drugs. 2014 Apr;32(2):330-9. doi: 10.1007/s10637-013-0042-9. Epub 2013 Nov 1. Invest New Drugs. 2014. PMID: 24173967 Free PMC article. Clinical Trial.
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, Hsu SD, Zafar SY, Wallace J, Starodub AN, Strickler JH, Pang H, Nixon AB, Hurwitz HI. Rangwala F, et al. Among authors: strickler jh. Invest New Drugs. 2014 Aug;32(4):700-9. doi: 10.1007/s10637-014-0089-2. Epub 2014 Apr 9. Invest New Drugs. 2014. PMID: 24711126 Free PMC article. Clinical Trial.
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.
Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S. Strickler JH, et al. Cancer Discov. 2018 Feb;8(2):164-173. doi: 10.1158/2159-8290.CD-17-1009. Epub 2017 Dec 1. Cancer Discov. 2018. PMID: 29196463 Free PMC article.
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).
Clarke JM, Blobe GC, Strickler JH, Uronis HE, Zafar SY, Morse M, Dropkin E, Howard L, O'Neill M, Rushing CN, Niedzwiecki D, Watson H, Bolch E, Arrowood C, Liu Y, Nixon AB, Hurwitz HI. Clarke JM, et al. Cancer Chemother Pharmacol. 2019 Oct;84(4):909-917. doi: 10.1007/s00280-019-03916-0. Epub 2019 Aug 23. Cancer Chemother Pharmacol. 2019. PMID: 31444620 Free PMC article. Clinical Trial.
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
Strickler JH, Rushing CN, Niedzwiecki D, McLeod A, Altomare I, Uronis HE, Hsu SD, Zafar SY, Morse MA, Chang DZ, Wells JL, Blackwell KL, Marcom PK, Arrowood C, Bolch E, Haley S, Rangwala FA, Hatch AJ, Nixon AB, Hurwitz HI. Strickler JH, et al. BMC Cancer. 2019 Nov 1;19(1):1032. doi: 10.1186/s12885-019-6234-8. BMC Cancer. 2019. PMID: 31675952 Free PMC article. Clinical Trial.
Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver Metastases.
Creasy JM, Napier KJ, Reed SA, Zani S Jr, Wong TZ, Kim CY, Wildman-Tobriner B, Strickler JH, Hsu SD, Uronis HE, Allen PJ, Lidsky ME. Creasy JM, et al. Among authors: strickler jh. Ann Surg Oncol. 2020 Dec;27(13):5086-5095. doi: 10.1245/s10434-020-08972-y. Epub 2020 Aug 10. Ann Surg Oncol. 2020. PMID: 32779054
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
Strickler JH, Rushing CN, Uronis HE, Morse MA, Niedzwiecki D, Blobe GC, Moyer AN, Bolch E, Webb R, Haley S, Hatch AJ, Altomare IP, Sherrill GB, Chang DZ, Wells JL, Hsu SD, Jia J, Zafar SY, Nixon AB, Hurwitz HI. Strickler JH, et al. Oncologist. 2021 Jun;26(6):465-e917. doi: 10.1002/onco.13678. Epub 2021 Feb 9. Oncologist. 2021. PMID: 33469991 Free PMC article. Clinical Trial.
376 results